1. Home
  2. AMS vs IBIO Comparison

AMS vs IBIO Comparison

Compare AMS & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Shared Hospital Services

AMS

American Shared Hospital Services

SELL

Current Price

$1.04

Market Cap

10.0M

Sector

Health Care

ML Signal

SELL

IBIO

iBio Inc.

SELL

Current Price

$0.75

Market Cap

52.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AMS
IBIO
Founded
1980
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
52.8M
IPO Year
1995
2009

Fundamental Metrics

Financial Performance
Metric
AMS
IBIO
Price
$1.04
$0.75
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $5.69
AVG Volume (30 Days)
10.0K
★ 487.9K
Earning Date
11-12-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.71
EPS
N/A
★ N/A
Revenue
★ $19,714,000.00
N/A
Revenue This Year
$16.37
$990.00
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 0.81
N/A
52 Week Low
$0.98
$0.68
52 Week High
$2.39
$3.82

Technical Indicators

Market Signals
Indicator
AMS
IBIO
Relative Strength Index (RSI) 25.50 39.75
Support Level N/A $0.71
Resistance Level $1.75 $0.85
Average True Range (ATR) 0.06 0.06
MACD -0.01 0.01
Stochastic Oscillator 20.59 30.59

Price Performance

Historical Comparison
AMS
IBIO

About AMS American Shared Hospital Services

American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.

About IBIO iBio Inc.

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Share on Social Networks: